Press release from Companies
Published: 2026-03-13 08:30:00
Notice to convene the Annual General Meeting (the "General Meeting") of Cessatech A/S (CVR no. 41 29 30 55) ("Cessatech" or the "Company")
The Board of Directors hereby convenes the Annual General Meeting of Cessatech to be held on:
Monday, 30 March 2026, at 9:00 am (CET)
The General Meeting will be held at the Company's address: Strandvejen 60, 2900 Hellerup, Denmark.
Agenda
Complete Proposals
Re 1: Election of chairman of the meeting
The Board of Directors proposes that Mikkel Rostock-Jensen is elected as the Chairman of the General Meeting.
Re 2: Management’s report on the activities of the Company in the past financial year
An oral report on the activities of the Company in the past financial year will be presented. The Board of Directors proposes that the report is noted by the General Meeting.
Re 3: Approval of the audited Annual Report 2025
The Board of Directors proposes that the Company’s Annual Report with the auditors’ report for the financial year 2025 is adopted. The Annual Report is available on the Company’s website.
Re 4: Resolution on the covering of losses in accordance with the adopted Annual Report 2025
The Board of Directors proposes that the net loss for the financial year 2025 of tDKK 10,904 be carried forward to the next financial year in accordance with the adopted Annual Report 2025.
Re 5: Election of members to the Board of Directors
The Board of Directors proposes that the following members be re-elected to the Board of Directors: Charlotte Videbæk, Flemming Steen Jensen, Martin Olin and Rachel Curtis Gravesen.
Re 6: Election of auditor
The Board of Directors proposes re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 33 77 12 31, as the Company’s auditor.
Proxy
The shareholders may vote by proxy for the General Meeting. A proxy and voting correspondence form can be found on the company’s website (www.cessatech.com). Voting by proxy may be exercised by completing and returning the proxy and correspondence form by email to info@cessatech.com. Proxies shall be submitted no later than 27 March 2026 before 23.59
Voting by Correspondence
Shareholders may instead of voting in person at the General Meeting choose to vote by mail, i.e. voting in writing prior to the General Meeting. A proxy and voting by correspondence form can be found on the company’s website (www.cessatech.com). Any shareholder who wishes to vote by mail shall submit the proxy and voting by correspondence form, duly completed and signed, by email to info@cessatech.com. Votes delivered by mail must be submitted no later than 27 March 2026 before 16.00 and cannot be revoked.
Information
To adopt the proposals under items 1, 3, 4, 5 and 6, a simple majority of the votes cast is required.
The Company’s share capital is nominally DKK 3,715,287.40 divided into 18,576,437 shares of nominally DKK 0.20. Each share of nominally DKK 0.20 carries one vote at the General Meeting.
The following documents are available on the Company’s website (www.cessatech.com/investor/general-meetings/) and at the Company’s registered office from 13 March 2026:
A shareholder’s right to attend and vote at the General Meeting is determined at the registration date, 23 March 2026, according to the shareholders’ register.
Shareholders who are entitled to attend the General Meeting and who wish to attend the General Meeting must request an admission card no later than 27 March 2026 at 23:59 (CET) by email to info@cessatech.com.
The request must be made according to the above guidelines. The shareholder must fill in and sign the proxy and voting by correspondence form.
The shareholders have the right to ask questions in relation to the items on the agenda to be discussed at the General Meeting. The questions can be made in writing before the General Meeting or at the General Meeting.
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
About Cessatech
Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company’s lead program, CT001, is advancing toward near-term commercialization. Cessatech operates an efficient, partnership-driven model, combining a lean, experienced team with best-in-class partners for development, manufacturing and commercial execution across key markets. Headquartered in Hellerup, Denmark. Cessatech is led by a seasoned leadership team with a strong track record in drug development and product launches in Europe, the US and Asia.
